Achilles Therapeutics (ACHL) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Achilles Therapeutics has reported a cash position of $86.1 million as of September 30, 2024, with an additional $12.8 million received as a cash R&D tax credit in October. The company is seeking strategic options with BofA Securities following the discontinuation of its TIL-based cNeT program. Financial highlights reveal a net loss of $19.6 million for the third quarter, reflecting increased R&D expenses compared to the previous year.
For further insights into ACHL stock, check out TipRanks’ Stock Analysis page.
